Navigation Links
Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease
Date:10/15/2007

ROCKVILLE, Md., Oct. 15 /PRNewswire-USNewswire/ -- Patients with mid-range coronary artery disease are more likely to get relief from painful angina and less likely to have repeat procedures if they get bypass surgery rather than balloon angioplasty with or without a stent, according to a new report by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.

The analysis drew on 23 randomized controlled trials that compared treatments for patients with mid-range coronary disease treatable with either angioplasty or bypass surgery. As defined by the report, mid-range disease may occur in three ways: a single blockage of the vital left anterior descending artery, blockage of two arteries, or some forms of less-severe blockage of three arteries.

The report also found that for mid-range coronary artery disease, bypass surgery and angioplasty patients had about the same survival rates and similar numbers of heart attacks, but that bypass surgery presents a slightly higher risk of stroke within 30 days of the procedure. A summary of the report is posted today in the online version of Annals of Internal Medicine.

"Choosing a treatment for coronary disease has long been a difficult challenge," said AHRQ Director Carolyn M. Clancy, M.D. "But this new evidence-based report provides a vital reference to help doctors, patients, and their families make the best possible decision."

Coronary artery disease, a common type of heart disease, affects about 15 million Americans and is the leading cause of death for men and women. It occurs when cholesterol and fibrous tissue clog arteries that supply blood to the heart. When arteries narrow, diminished blood flow may starve the heart muscle of oxygen and nutrients. Intense and potentially disabling chest pain, called angina, occurs when the blood supply to the heart muscle is insufficient during exercise or stress. If blood flow through a coronary artery is
'/>"/>

SOURCE Agency for Healthcare Research & Quality
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
2. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
3. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
4. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
5. ArteFill 5-Year Data to Be Presented at American Society for Aesthetic Plastic Surgery Annual Meeting
6. New Cardioprotective Drug Could Provide Boost For Post-Bypass Surgery Heart Health
7. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
8. Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery
9. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
10. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
11. Study Shows Children With ADHD Who Start on Strattera are More Likely to Change Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
Breaking Medicine Technology:Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 1Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 2K State program will give young professionals skills to protect water resources 10693 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 2High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 3High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 4
...Host Conference Call at 9:00 a.m. EDT-, MONTVALE,...aq: MEMY ) today announced top-line data from the...ontrolled Phase 2a study,of MEM 1003, a neuronal L...sease. The trial enrolled 183 subjects with mild t...in the United States and included monotherapy,subj...
...N.J. and NEW YORK, Oct. 12 Daiichi Sankyo,Inc. an...d today that they,have signed a contract for a co-...hi Sankyo,s AZOR(TM), a fixed combination of two,a...odipine and the,angiotensin receptor blocker, olme... letter of intent for the co-promotion agreement o...
Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 2Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 3Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 4
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3
...ts act together to check the perilous trend of twi...artment has suggested a cap on the// embryo, allow...el set in motion by the Human Fertilization and Em... the wrong side of 30. Further IVF clinics w...
...be efficient on animals according to researchers a...ps we can cure HIV infection. This is our hope," s...tario. Clinical trials of the vaccine are expect...e to be careful because we have done the animal, t...
...wn the risk of Alzheimer's disease by reducing inf... recent communiqué. The finding// holds a clue as...in the 1960s and 1970s are at a lesser chance of d...ties of ceasing loss of brain cells, which is a ch...
...ged that AIDS is no more restricted to just risk g...ses are added each day according to statistics wit...bted to be AIDS positive. It is alarming to note t... too has more number of infections being spread th...
... affected only by thalassemia intermedia till Febr... positive.// Initially, blood transfusion wa...rsened, she underwent blood transfusion 10 times l...c kits from the jute baron Govind Sarda's firm; Mo...
...ed by scientists in the US attacks the malaria par...he disease that has kills one million// people a y...veloped by Walter Reed Army Institute of Research ...common, reported the science portal EurekAlert. ...
Other Medicine News:Health News:Thalassemic patient is now HIV positive due to faulty Diagnostic kit… 2
Microalbumin Linearity Control
Total IgE Control
Lyophilized Lipid Control
High-sensitive CRP Control
Medicine Products: